MMP2
MMP2
Overview
Matrix metalloproteinase-2 (MMP-2), encoded by the MMP2 gene (Wikidata: Q15327913), is a zinc-dependent endopeptidase belonging to the matrix metalloproteinase (MMP) family of extracellular proteases. It is also commonly referred to as gelatinase A or type IV collagenase, reflecting its ability to cleave type IV collagen—a principal structural component of basement membranes. MMP-2 requires a zinc ion coordinated within its catalytic domain for proteolytic activity, and its function is tightly regulated by endogenous inhibitors including tissue inhibitors of metalloproteinases (TIMPs), particularly TIMP-1 and TIMP-2. Under physiological conditions, MMP-2 participates in normal extracellular matrix (ECM) remodeling processes such as wound healing, angiogenesis, and tissue morphogenesis. Its activity is balanced against matrix assembly to maintain tissue homeostasis.
In pathological contexts, dysregulated MMP-2 expression and activity are strongly associated with tumor invasion, cancer metastasis, neovascularization, and inflammatory tissue destruction. MMP-2 acts in close functional concert with matrix metalloproteinase-9 (MMP-9), and together they are among the most studied proteases in cancer biology. Elevated MMP-2 has been documented across a broad range of malignancies including glioma, bladder cancer, gastric cancer, and osteosarcoma. Beyond oncology, MMP-2 also plays roles in diabetic retinopathy, ischemic stroke, metabolic liver disease, osteoporosis-associated angiogenesis, and temporomandibular joint disorders, making it a versatile biomarker and therapeutic target across multiple disease domains.
Focus of Latest Publications
Recent publications spanning 2026 collectively highlight MMP-2 as a central node in ECM remodeling, metastatic signaling, and therapeutic targeting across diverse disease models.
Cancer Metastasis and Invasion Several studies converge on MMP-2's role in enabling tumor cell invasion through basement membrane degradation. A computational study published in Computational Biology and Chemistry (PMID: 41604734) deployed a machine learning-driven virtual screening pipeline to identify novel MMP-2 inhibitors with improved selectivity and binding stability, framing MMP-2 explicitly as "a zinc-dependent endopeptidase which plays a key role in extracellular matrix remodeling and cancer metastasis." The pipeline integrated molecular docking and molecular dynamics simulations, offering a template for rational inhibitor design. Separately, a study in Cell Biology International (PMID: 42153635) investigated berberine chloride (BRB) in MDA-MB-231 and 4T1 breast cancer cell lines, demonstrating that BRB significantly downregulated MMP2 and MMP9 mRNA expression, thereby suppressing ECM remodeling and metastatic progression. This finding aligns with BRB's broader profile as an inducer of apoptosis and an inhibitor of cancer cell adhesion and migration. In gastric cancer, Molecular Genetics and Genomics (PMID: 42154344) reported that the novel biomarker KIRREL1 positively regulates MMP-2 and MMP-9 alongside the EMT marker Vimentin, positioning MMP-2 as a downstream effector of the epithelial-to-mesenchymal transition (EMT) pathway that drives malignancy.
Drug Discovery and Targeted Delivery MMP-2's proteolytic activity has been exploited for tumor-targeted drug delivery. A study in Analytical Chemistry (PMID: 41999640) engineered an enzyme-activatable nanosystem for imaging and therapy of breast cancer bone metastasis, assembling gold nanotriangles functionalized with an MMP-2-cleavable Cy5 peptide alongside the tumor-targeting aptamer AS1411. This nanosystem leveraged MMP-2 overactivity in the tumor microenvironment to trigger payload release and enable real-time imaging while delivering synergistic Zn²⁺-interference photothermal therapy. In a related approach, Molecular Pharmaceutics (PMID: 41920242) described EGFR-targeted membranolytic Peptides modified with MMP-2 cleavage sequences, achieving cancer-specific cytotoxicity in vitro and tumor growth reduction in vivo by exploiting MMP-2 as a biomarker for selective activation. Additionally, a study in Bioorganic & Medicinal Chemistry (PMID: 41785527) identified novel thiazolidinedione-based hybrid compounds (HB68 and HB147) in HCT116 colorectal cancer cells that suppressed MMP-2 and MMP-9 protein expression while upregulating pro-apoptotic markers including BAX, Caspases-3, -7, and -9, confirming intrinsic apoptosis activation alongside invasion suppression.
Glioma Radiogenomics and Survival Prediction A radiogenomics study published in Cell Reports. Medicine (PMID: 42127900) identified MMP-2 as one of seven hub genes—alongside MMP-9, CXCL8, TIMP1, IL-6, COL1A2, and CCL2—predictive of glioma survival and ECM remodeling patterns detectable through MRI. This integrative approach linking imaging signatures to molecular biology underscores MMP-2's value as a prognostic biomarker beyond direct protein measurement.
bladder cancer and Mechanobiology Published in ACS Applied Materials & Interfaces (PMID: 42203192), a study of bladder cancer spheroids demonstrated that matrix stiffness governs metabolic and invasive adaptation: HT1376 spheroids embedded in soft matrices activated glycolysis (HK2) alongside MMP-2-dependent ECM remodeling, yet remained largely non-migratory—revealing a decoupling between invasive priming and active motility, and highlighting MMP-2 as a component of mechano-metabolic tumor adaptation.
Osteosarcoma and Nanoparticle Therapy In Scientific Reports (PMID: 42108266), palladium nanoparticles synthesized using Psidium guajava leaf extract (PdNPs-PGLE) were shown to suppress MMP-2 and MMP-9 expression in osteosarcoma cells while increasing Bax, cleaved caspase-3, and TP53 levels and decreasing Bcl-2 and CDK2, confirming synergistic antitumor activity through apoptosis induction and metastasis suppression.
Angiogenesis, Ischemic Stroke, and Vascular Biology MMP-2's role in vascular remodeling was examined in two distinct contexts. In a study on ischemic stroke (ACS Applied Bio Materials, PMID: 42095375), an ECM hydrogel designed for targeted delivery of bFGF and an angiopoietin-1 mimetic peptide enhanced neurovascular regeneration partly through inhibition of MMP-2 overactivity, thereby reducing vascular permeability. In the context of postmenopausal osteoporosis (Journal of Molecular Histology, PMID: 42126726), dendrobine treatment markedly augmented endothelial tube formation and upregulated VEGF, MMP-2, and MMP-9 via inhibition of the Hippo signaling pathway, illustrating that MMP-2 can also serve a pro-regenerative angiogenic function when appropriately contextualized.
diabetic retinopathy A study evaluating Vasant Kusumakar Rasa, a traditional Ayurvedic formulation, in diabetic rats (Journal of Molecular Histology, PMID: 42209874) measured MMP-2 and VEGF expression in ocular tissue, finding that treatment reduced neovascularization, oxidative stress, and inflammation while improving retinal function, implicating MMP-2 in the pathological angiogenic cascade of diabetic retinopathy.
Mesenchymal Stem Cells and Metabolic Liver Disease In a model of metabolic dysfunction-associated steatohepatitis (MASH), three-dimensional aggregate culture of human umbilical cord-derived mesenchymal stem cells enhanced their matrix-remodeling properties, reflected by elevated MMP-2 and MMP-9 expression in vitro (Stem Cells and Development, PMID: 41988929). This was accompanied by upregulation of hepatocyte growth factor, TNF-stimulated gene 6, cyclooxygenase-2 (Prostaglandin-endoperoxide synthase 2), prostaglandin E synthase, and B-cell lymphoma-2, suggesting that MMP-2 expression is part of a broader paracrine and mechanosensitive therapeutic phenotype in 3D-cultured stem cells.
Temporomandibular Joint Disorders A twin-discordant study in Molecular Biology Reports (PMID: 42132960) profiled matrix remodeling proteins—including MMP-2, MMP-9, TIMP-1, and TIMP-2—alongside inflammatory biomarkers (IL-6, IL-10), oxidative markers (MDA, superoxide dismutase, catalase), and neurotrophic factors (Brain-derived neurotrophic factor, β-NGF, α2M) in subjects with pain-related temporomandibular disorders (TMD), establishing MMP-2 as part of a multi-analyte signature distinguishing affected from unaffected twins.